Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.54 |
| ▸ | RAB9A | P51151 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.54 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458633 | 0.78 | ALDH1A1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL26314552 | 0.69 | ENPP2 (0.42) | KDM4ETSHR | |
| SCHEMBL38656446 | 0.69 | ENPP2 (0.42) | KDM4ETSHR | |
| SCHEMBL4151815 | 0.69 | ALDH1A1 (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10388599 | 0.68 | KDM4E (0.66) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10236246 | 0.67 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL23447727 | 0.66 | ALDH1A1 (0.63) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10279120 | 0.66 | NPC1 (0.76) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL14668828 | 0.64 | CA2 (0.54) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL29580407 | 0.62 | CA2 (0.48) | KMT2AATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480556-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036128-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, RTF2, HCCS | NPC1 979/4885RAB9A 733/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.